AFT Pharmaceuticals has kicked off a commercialisation program for its patented Maxigesic IV (intravenous) formulation, signing a licensing agreement with South Korean firm Kyongbo Pharmaceutical Co Limited.
Maxigesic IV is a paracetamol 1000mg + ibuprofen 300mg solution for infusion, and has been developed as a line extension to Maxigesic tablets for use post-operatively in hospitals as an alternative to opioid-based IV analgesics.
The product registration process in South Korea is planned for the near future, with sales expected to commence in 2019/20.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Nov 18
